Document:

EX-10.13

 Exhibit 10.13 

THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN
AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT,
THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 FORM OF CLASS B WARRANT TO PURCHASE COMMON STOCK 

OF 
 GREAT BASIN
SCIENTIFIC, INC. 
 Great Basin Scientific, Inc. 

THIS WARRANT (the “Class B Warrant”) certifies that, for value received, (the “Holder”), is entitled, upon the terms and
subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on
                 , 2021 (the “Expiration Date”) but not thereafter, to subscribe for and purchase from Great Basin Scientific, Inc., a Delaware
corporation (the “Company”), up to [CALCULATED AS 100 % OF THE PREFERRED STOCK ISSUED TO THE INVESTOR PURSUANT TO THE PURCHASE AGREEMENT] shares of the Common Stock of the Company (the “Class B Warrant Shares”)
at a purchase price equal to $0.001 per share (the “Exercise Price”). This Class B Warrant is one of a series of similar warrants to purchase Common Stock issued pursuant to that certain Series D Preferred Stock and Warrant Purchase
Agreement, dated of even date herewith, by and between the Company and the purchasers signatory thereto (the “Purchase Agreement”). All such warrants are referred to herein, collectively, as the “Class B Warrants.”

 Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Purchase
Agreement. 
 Section 2. Exercise. 

a) Exercise of Class B Warrant. Exercise of the purchase rights represented by this Class B Warrant may be made at any time or times on
or after the Initial Exercise Date and on or before the Expiration Date by delivery to the Company of a duly executed facsimile copy of the 

 
Notice of Exercise Form annexed hereto as Exhibit A and the payment of the Exercise Price for the Class B Warrant Shares so purchased by wire transfer or cashier’s check drawn on a
United States bank. Upon exercise of the Class B Warrant, the Company shall issue and deliver to the person or person entitled to receive the same, a certificate or certificates for the number of Class B Warrant Shares issuable upon such exercise.

 b) Cashless Exercise. In the event that the Company’s common stock is then traded on a securities exchange, and a
registration statement covering the resale of the Class B Warrant Shares has not been filed by the Company and first declared effective by the SEC, then the Holder may exchange this Class B Warrant on a cashless basis, in whole or in part (a
“Cashless Exercise”), for the number of Class B Warrant Shares determined in accordance with this Section 2(b) by delivery to the Company of a duly executed facsimile copy of the Notice of Exercise Form annexed hereto
indicating the Holder’s intent to effect such exchange, provided, however, that the right of a Holder to effect a Cashless Exercise pursuant to this Section 2(b) shall terminate at such time as a registration statement is
first declared effective by the SEC. In connection with any Cashless Exercise, the Company shall issue to the Holder the number of Class B Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where: 

 

					
	(A)	  	=	  	the average closing stock price of the Company’s common stock on its principal stock exchange for the five Trading Days immediately preceding the date of such election;
			
	(B)	  	=	  	the Exercise Price; and
			
	(X)	  	=	  	the number of shares covered by the Class B Warrant which the Holder has elected to exchange pursuant to this Section 2(b).

 c) Mechanics of Exercise. 

i. Authorization of Common Stock. The Company covenants that during the period the Class B Warrant is outstanding, it
will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of all of the shares of Common Stock issuable upon the exercise of the Class B Warrant. The Company further covenants that its
issuance of this Class B Warrant shall constitute full authority to its officers who are charged with the duty of executing certificates to execute and issue the necessary certificates for the Class B Warrant Shares upon the exercise of the purchase
rights under this Class B Warrant. The Company covenants that the Class B Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Class B Warrant will, upon exercise of the purchase rights represented by this
Class B Warrant, be duly authorized, validly issued, fully paid and non-assessable and free from all taxes, liens and charges in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).
The Company will take all such reasonable action as may be necessary to assure that the Class B Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon
which the Common Stock may be listed. 

  
 2 

 ii. Delivery of Certificates Upon Exercise. Certificates for the Class B
Warrant Shares purchased hereunder shall be delivered to the Holder within three (3) Trading Days from the delivery to the Company of the Notice of Exercise Form, surrender of this Class B Warrant and payment of the Exercise Price as set forth
above (“Class B Warrant Delivery Date”). This Class B Warrant shall be deemed to have been exercised on the date the payment of the principal amount is received by the Company. The Class B Warrant Shares shall be deemed to have been
issued, and the Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such security for all purposes, as of the date the Class B Warrant has been exercised by payment to the Company of the
principal amount and all taxes required to be paid by the Holder, if any, pursuant to Section 2(c)(ii) prior to the issuance of such security, have been paid. 

iii. Delivery of New Class B Warrants Upon Exercise. If this Class B Warrant shall have been exercised in part, the
Company shall, at the time of delivery of the certificate or certificates representing the Class B Warrant Shares, deliver to the Holder a new Class B Warrant evidencing the rights of such Holder to purchase the unpurchased Class B Warrant Shares
called for by this Class B Warrant, which new Class B Warrant shall in all other respects be identical with this Class B Warrant. 

iv. Rescission Rights. If the Company fails to deliver to the Holder a certificate or certificates representing the
Class B Warrant Shares pursuant to Section 2(c)(ii) by the Class B Warrant Delivery Date, then the Holder will have the right to rescind such exercise. 

v. Charges, Taxes and Expenses. Issuance of certificates for Class B Warrant Shares shall be made without charge to the
Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such
name or names as may be directed by the Holder; provided, however, that in the event certificates for Class B Warrant Shares are to be issued in a name other than the name of the Holder, this Class B Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder; and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. 

vi. Closing of Books. The Company will not close its records in any manner which prevents the timely exercise of this
Class B Warrant, pursuant to the terms hereof. 
 Section 3. Certain Adjustments. 

a) Stock Dividends and Splits. If the Company, at any time while this Class B Warrant is outstanding: (A) pays a stock dividend or
otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issuable
by the Company pursuant to the Class B Warrants), (B) subdivides outstanding shares of Common Stock into a larger number of shares, (C) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller
number of shares, or (D) issues by 

  
 3 

 
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be
the number of shares of Common Stock (excluding treasury shares, if any) outstanding before such event and of which the denominator shall be the number of shares of Common Stock outstanding after such event. The number of shares of common stock
exerciseable pursuant to this Class B Warrant shall also be proportionately increased in the case of a subdivision or stock dividend, or similar event and proportionately decreased in the case of a combination or similar event. Any adjustment made
pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in
the case of a subdivision, combination or reclassification. 
 b) Fundamental Transaction. In case of any reclassification, capital
reorganization, exchange of shares, liquidation, recapitalization or change of the Common Stock (other than as a result of a subdivision, combination, stock dividend or reclassification provided for in Section 3(a) hereof), or in case of any
consolidation or merger of the Company with or into another corporation or entity (other than a merger with a subsidiary in which merger the Company is the continuing corporation and which does not result in any reclassification or capital
reorganization or change of the outstanding Common Stock) or in case of any sale, lease or conveyance to another corporation or entity of all or substantially all of the assets of the Company, then the Company shall, as a condition precedent to such
transaction, cause lawful and effective provisions to be made (and duly executed documents evidencing the same from the Company or its successor shall be delivered to the Holder) so that the Holder shall have the right thereafter upon exercise of
this Class B Warrant, to purchase the kind and amount of shares of stock and other securities and property receivable upon such reclassification, capital reorganization, exchange of shares, liquidation, recapitalization, change, consolidation,
merger, sale or conveyance by a holder of the number of shares of Common Stock which might have been received upon conversion of this Class B Warrant immediately prior to such reclassification, capital reorganization, exchange of shares,
liquidation, recapitalization, change, consolidation, merger, sale or conveyance, and in any such event, such provision shall include provision for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for
herein. The Company shall not effect any such consolidation, merger, sale, transfer or other disposition described above, unless prior to or simultaneously with the consummation thereof the successor corporation (if other than the Company) resulting
from such consolidation or merger or the corporation purchasing or otherwise acquiring such assets shall assume, by written instrument executed and mailed or delivered to the Holder of this Class B Warrant at the last address of the Holder appearing
on the books of the Company, the obligation to deliver to the Holder such shares of stock, securities, cash or properties as, in accordance with the foregoing provisions, the Holder may be entitled to acquire. The above provisions of this paragraph
shall similarly apply to successive reorganizations, reclassifications, exchanges, liquidations, recapitalizations, changes, consolidations, mergers, sales, transfers or other dispositions, if any. 

c) Calculations. All calculations and adjustments to the Exercise Price under this Section 3 shall be made to the nearest cent or
the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any)
outstanding. 

  
 4 

 d) Notice to Holders. The Company shall promptly give written notice of any adjustment
under this Section 3 to each Holder, which notice shall include a brief statement of the facts requiring such adjustment. 
 e)
Voluntary Adjustment By Company. The Company may at any time during the term of this Class B Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company.

 f) Adjustment for Certain Share Issuances. Until the Expiration Date, if the Company shall issue any Common Stock except for the
Excluded Issuances (as defined below), prior to the complete exercise of this Class B Warrant for a consideration less than the Exercise Price that would be in effect at the time of such issuance, then, and thereafter successively upon each such
issuance, the Exercise Price shall be reduced to such other lower price. For purposes of this adjustment, the issuance of any security or debt instrument of the Company carrying the right to convert such security or debt instrument into Common Stock
or of any warrant, right or option to purchase Common Stock shall result in an adjustment to the Exercise Price upon the issuance of the above-described security, debt instrument, warrant, right, or option if such issuance is at a price lower than
the Exercise Price in effect upon such issuance and again at any time upon any actual, permitted, optional, or allowed issuances of shares of Common Stock upon any actual, permitted, optional, or allowed exercise of such conversion or purchase
rights if such issuance is at a price lower than the Exercise Price in effect upon any actual, permitted, optional, or allowed such issuance. A convertible instrument (including a right to purchase equity of the Company) issued, subject to an
original issue or similar discount or which principal amount is directly or indirectly increased after issuance will be deemed to have been issued for the actual cash amount received by the Company in consideration of such convertible instrument.
The reduction of the Exercise Price described in this Section 5 is in addition to the other rights of the Holder described herein. 

“Excluded Issuances” means: (i) the Company’s issuance of securities in connection with bona fide strategic license
agreements and other bona fide partnering arrangements so long as such issuances are not for the purpose of raising capital and which holders of such securities or debt are not at any time granted registration rights, (ii) the Company’s
issuance of Common Stock or the issuances or grants of options to purchase Common Stock to employees, directors, and consultants, pursuant to approved equity compensation plans, (iii) securities upon the exercise or exchange of or conversion of
any securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement; and (iv) the shares issuable upon exercise of the Class B Warrants. 

g) Maximum Exercise. The Holder shall not be entitled to exercise this Class B Warrant on an exercise date, in connection with that
number of shares of Common Stock which would be in excess of the sum of (i) the number of shares of Common Stock beneficially owned by the Holder and its affiliates on an exercise date, and (ii) the number of shares of Common Stock
issuable upon the exercise of this Class B Warrant with respect to which the determination of this limitation is being made on an exercise date, which would result in beneficial ownership 

  
 5 

 
by the Holder and its affiliates of more than 4.99% of the outstanding shares of Common Stock on such date. For the purposes of the immediately preceding sentence, beneficial ownership shall be
determined in accordance with Section 13(d) of the Exchange Act and Rule 13d-3 thereunder. Subject to the foregoing, the Holder shall not be limited to aggregate exercises which would result in the issuance of more than 4.99%. The restriction
described in this paragraph may be waived, in whole or in part, upon sixty-one (61) days prior notice from the Holder to the Company to increase such percentage. 

Section 4. Transfer of Class B Warrant. 

a) Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Sections 5(a) and 4(d)
hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Class B Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Class B Warrant at the principal office of the Company, together
with a written assignment of this Class B Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such
surrender and, if required, such payment, the Company shall execute and deliver a new Class B Warrant or Class B Warrants in the name of the assignee or assignees and in the denomination or denominations specified in such instrument of assignment,
and shall issue to the assignor a new Class B Warrant evidencing the portion of this Class B Warrant not so assigned, and this Class B Warrant shall promptly be cancelled. A Class B Warrant, if properly assigned, may be exercised by a new holder for
the purchase of Class B Warrant Shares without having a new Class B Warrant issued. 
 b) New Class B Warrants. This Class B Warrant
may be divided or combined with other Class B Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Class B Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Class B Warrant or Class B Warrants in exchange
for the Class B Warrant or Class B Warrants to be divided or combined in accordance with such notice. 
 c) Class B Warrant Register.
The Company shall register this Class B Warrant, upon records to be maintained by the Company for that purpose (the “Class B Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Class B Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary 

d) Transfer Restrictions. If, at the time of the surrender of this Class B Warrant in connection with any transfer of this Class B
Warrant, the transfer of this Class B Warrant shall not be registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws, the Company may require, as a condition of
allowing such transfer (i) that the Holder or transferee of this Class B Warrant, as the case may be, furnish to the Company a written opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in
comparable transactions) to the effect that such transfer may be made without registration under the Securities Act and under applicable state securities or blue sky laws, (ii) that the holder or transferee execute and deliver

  
 6 

 
to the Company an investment letter in form and substance acceptable to the Company and (iii) that the transferee be an “accredited investor” as defined in Rule 501(a) promulgated
under the Securities Act or a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act. 
 Section 5.
Miscellaneous. 
 a) Title to the Class B Warrant. Prior to the Expiration Date and subject to compliance with applicable laws
and Section 4 of this Class B Warrant, this Class B Warrant and all rights hereunder are transferable, in whole or in part, at the office or agency of the Company by the Holder in person or by duly authorized attorney, upon surrender of this
Class B Warrant together with the Assignment Form annexed hereto properly endorsed. The transferee shall sign an investment letter in form and substance reasonably satisfactory to the Company. 

b) No Rights as Shareholder Until Exercise. This Class B Warrant does not entitle the Holder to any voting rights or other rights as a
shareholder of the Company prior to the exercise hereof. Upon the surrender of this Class B Warrant and the payment of the aggregate Exercise Price, the Class B Warrant Shares so purchased shall be and be deemed to be issued to such Holder as the
record owner of such shares as of the close of business on the later of the date of such surrender or payment. 
 c) Loss, Theft,
Destruction or Mutilation of Class B Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Class B Warrant or any certificate relating to
the Class B Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Class B Warrant, shall not include the posting of any bond), and upon surrender and cancellation
of such Class B Warrant or certificate, if mutilated, the Company will make and deliver a new Class B Warrant or certificate of like tenor and dated as of such cancellation, in lieu of such Class B Warrant or certificate. 

d) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall be a Saturday, Sunday or a legal holiday, then such action may be taken or such right may be exercised on the next succeeding day not a Saturday, Sunday or legal holiday. 

e) No Impairment. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including,
without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Class B Warrant or the Class B Warrant Shares, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to
protect the rights of Holder as set forth in this Class B Warrant and the Class B Warrant Shares against impairment. Without limiting the generality of the foregoing, the Company will (a) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and non-assessable Class B Warrant Shares upon the exercise of this Class B Warrant and (b) use commercially reasonable efforts to obtain all such authorizations, exemptions or
consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the 

  
 7 

 
Company to perform its obligations under this Class B Warrant and the Class B Warrant Shares. Before taking any action which would result in an adjustment in the Class B Warrant Shares for which
this Class B Warrant is exercisable, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. 

f) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Class B Warrant shall be
determined in accordance with the provisions of the Purchase Agreement. 
 g) Restrictions. The Holder acknowledges that the Class B
Warrant Shares acquired upon the exercise of this Class B Warrant, if not then registered, will have restrictions upon resale imposed by state and federal securities laws. 

h) Non-waiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that all rights hereunder terminate on the Expiration Date. If the Company willfully and knowingly fails to comply with any
provision of this Class B Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’
fees, including those of appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. 

i) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be
delivered in accordance with the notice provisions of the Purchase Agreement. 
 j) Limitation of Liability. No provision hereof, in
the absence of any affirmative action by Holder to exercise this Class B Warrant or purchase Class B Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase price
of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. 

k) Remedies. Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be
entitled to specific performance of its rights under this Class B Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Class B Warrant and
hereby agrees to waive the defense in any action for specific performance that a remedy at law would be adequate. 
 l) Successors and
Assigns. Subject to applicable securities laws, this Class B Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of
Holder. The provisions of this Class B Warrant are intended to be for the benefit of all Holders from time to time of this Class B Warrant and shall be enforceable by any such Holder. 

m) Modification. The provisions of the Class B Warrants may from time to time be amended, modified or waived, if such amendment,
modification or waiver is in writing and 

  
 8 

 
consented to by the Company and holders of at least a majority of the outstanding Class B Warrants (based on the number of Class B Warrant Shares underlying the Class B Warrants). Any such
amendment, modification or wavier shall be binding upon the Holder of this Class B Warrant regardless of whether the Holder consented to such amendment, modification or wavier; provided that nothing shall prevent the Company and the Holder from
consenting to amendments, modifications or waivers to this Class B Warrant that affect or are applicable to the Holder only. 
 n)
Severability. Wherever possible, each provision of this Class B Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Class B Warrant shall be prohibited by or invalid
under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Class B Warrant. 

o) Headings. The headings used in this Class B Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Class B Warrant. 
 *        *        *

  
 9 

 IN WITNESS WHEREOF, the Company has caused this Class B Warrant to be executed by its officer
thereunto duly authorized. 
 Dated:                  , 2014 

 

			
	GREAT BASIN SCIENTIFIC, INC.
		
	By:	 	  

		
		 	Name:
		
		 	Title:

  
 10 

 Exhibit A 

NOTICE OF EXERCISE 
 TO: GREAT BASIN
SCIENTIFIC, INC. 
 (1) The undersigned hereby elects to purchase shares of Common Stock of Great Basin Scientific, Inc. pursuant to the terms of the
attached Class B Warrant, and tenders herewith payment in full, together with all applicable transfer tax; 
 (2) Payment shall take the form of (check
applicable box): 
  ̈ lawful money of the United States; or 

 ̈ if Cashless Exercise is permitted in accordance with Section 2(b), the cancellation of
Class B Warrant Shares, in accordance with the formula set forth in subsection 2(b). 
 (3) Please issue a certificate or certificates representing said
Common Stock in the name of the undersigned or in such other name as is specified below (please include social security or other tax identification number): 
  

					
		  	  
	 	
			
		  	  
	 	
			
		  	  
	 	

 (4) The Common Stock shall be delivered to the following: 

 

					
		  	  
	 	
			
		  	  
	 	
			
		  	  
	 	

 (5) The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of
1933, as amended. 
 [SIGNATURE OF HOLDER] 
  

			
	Name of Investing Entity or Individual:	  	  

  

			
	Signature of Authorized Signatory of Investing Entity or Individual:	  	  

  

			
	Name of Authorized Signatory:	  	  

  

			
	Title of Authorized Signatory:	  	  

  

			
	Date:	  	  

  
 11 

 ASSIGNMENT FORM 

(To assign the foregoing warrant, execute 

this form and supply required information. 

Do not use this form to exercise the warrant.) 

FOR VALUE RECEIVED, the foregoing Class B Warrant and all rights evidenced thereby are hereby assigned to 

 
  

					
			
		  	whose address is	  	  

			
		  		  	  

			
		  		  	  

			
		  		  	  

			
		  		  	  

			
		  	 Dated:
	  	
			
		  	Holder’s Signature:	  	
			
		  	Holder’s Address:	  	

 Signature Guaranteed: 
 NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Class B Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of
corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Class B Warrant. 

  
 12EX-10.14

 Exhibit 10.14 

LICENSE AND SUPPLY AGREEMENT 
 This License and
Supply Agreement (the “Agreement”), effective as of January 9, 2009 (the “Effective Date”), is entered into by and between BioHelix Corporation, a Massachusetts corporation with principal offices at 32 Tozer Road, Beverly,
Massachusetts 01916 (“BioHelix”), and Great Basin Scientific Corporation, a Nevada corporation with principal offices at 405 South Main Street, Suite 810, Salt Lake City, UT 84111, (“Great Basin”). 

BACKGROUND 
 A. Whereas BioHelix has developed
the Product (as defined below) for amplification of analytes; 
 B. Whereas Great Basin develops, manufactures and markets proprietary DNA testing systems
for the screening, monitoring and diagnosis of human diseases, and intends to develop Assay Products (as defined below) as set forth herein; and 
 C.
Whereas Great Basin desires to acquire from BioHelix the Products for purposes of developing, commercializing, and distributing Assay Products in the Territory in the Fields, and BioHelix desires to supply Great Basin with the Products and to grant
Great Basin a non-exclusive right to utilize certain of BioHelix’s Intellectual Property Rights in the development, manufacture and commercialization of Assay Products in the Territory, and Great Basin desires to accept such supply and license.

 NOW THEREFORE, for and in consideration of the covenants, conditions, and undertakings hereinafter set forth, it is agreed by and between the parties as
follows: 
 ARTICLE 1 

DEFINITIONS 
 1.1 “Affiliate” means any
entity that directly or indirectly owns, is owned by or is under common ownership with a party hereto, where “owns” or “ownership” means direct or indirect possession and/or control of at least fifty percent (50%) of the
outstanding voting securities of a corporation or a comparable equity interest in any other type of entity. 
 1.2 “Assay Products” includes ASRs,
RUOs and IVD Kits manufactured by Great Basin and covered by Biohelix Intellectual Property Rights that are intended for use in the identification, screening, diagnosis, staging, predisposition, prognosis, monitoring, or treatment of the disease in
the Field, and comprise any combination of: (i) reagents; (ii) controls and calibrators, (iii) ancillary materials (e.g. buffers, reporter dyes, capture sequence, etc.); and (iv) labeling and instructions for use; all as
necessary to perform a Test or Tests for purposes of generating clinical test results. 
 1.3 “Calendar Year” shall mean each twelve-month
(12-month) period during the term of this Agreement that begins on January 1, and ends on December 31. 
  

“[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 1 

 1.4 “Consumer Price Index” (“CPI”) means the index of consumer prices, as published by the
United States Department of Labor, used to measure the change in the cost of basic goods and services in comparison with a previous base period. 
 1.5
“End User” shall mean a consumer of Assay Products that obtains Assay Products for the purpose of generating Test results on behalf of itself or third parties and not for the purpose of re-selling the Assay Products. For purposes of
clarification, End Users shall not include Great Basin or any of its affiliated entities to the extent such entities do not perform Tests on behalf of third parties. In the event that Great Basin or any of its Affiliates perform Tests on behalf of
third parties, Great Basin or such entity shall be considered an End User only with respect to such testing services. 
 1.6 “Field(s)” means
human diagnostic testing using the amplification method disclosed and defined in the BioHelix Intellectual Property Rights, in combination with Great Basin’s solid surface chip based detection methods, for the detection of any two pathogens
identified in writing within 6 months of the execution of this agreement by Great Basin to BioHelix, including screening for the presence, identity, subtype and antibiotic resistance profile of the aforementioned pathogens. 

1.7 “BioHelix Intellectual Property Rights” means the (i) issued patents and patent applications listed in Exhibit B and future patents related
to the Method and the Product or claiming priority to such issued patents and patent applications, and all extensions, supplemental protection certificates, registrations, confirmations, reissues, reexaminations, renewals, divisionals,
continuations, or continuations-in-part thereof; (ii) all counterparts to any of the foregoing issued by or filed in any country or other jurisdiction (together with (i), the “Licensed Patents”); and (iii) copyrights, trademarks,
trade secrets, and know-how, to the extent each of (i), (ii) and (iii) relate to the Method and the Product, and any improvements, variations and successor versions of the Method and the Product. 

1.8 “Method” means Helicase-dependent amplification (“HDA”) as defined in the BioHelix Intellectual Property Rights. 

1.9 “Net Sales” means the total amounts invoiced by Great Basin, its subsidiaries and affiliates, for all Tests sold for value in arm’s length
transactions to non-Affiliate Subdistributors and End Users less all (i) trade, cash and volume discounts and rebates; (ii) allowances given or made for rejection or return of a previously sold Assay Product or for retroactive price
reductions; (iii) customs duties, sales taxes and/or use taxes, value added taxes, excise taxes and/or duties or tariffs and/or other similar taxes imposed upon the sale, transportation or delivery of Assay Products; and (iv) freight,
insurance and other direct shipment expenses; (v) royalties paid to any third party pursuant to a third party license agreement (excluding affiliates), if any, for Assay Products or components of Assay Products in any country provided that the
royalty payable to BioHelix shall not be reduced under this subsection (v) by more than fifty percent (50%) of the Royalties (as defined in Section 2.2). Net Sales shall not include: (i) reasonable amounts of Assay Products
furnished to a third party for which payment is not intended to be received, including, but not limited to, Assay Products distributed in connection with clinical trials or testing (before or after regulatory approval), as promotional, sample or
free goods, or as charitable distributions. 
  
 “[MATERIAL FROM THIS EXHIBIT HAS
BEEN REDACTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 2 

 1.10 “Quarter” means a period of three consecutive months of a Calendar Year starting on
January 1, April 1, July 1, or October 1. 
 1.11 “Products” include all products listed in Exhibit A. 

1.12 “Specifications” means the Product Specifications set forth in Exhibit A. 

1.13 “Territory” means all countries worldwide. 
 1.14
“Test” means a single use of the Product in the amplification of an analyte within the Field. 
 ARTICLE 2 

LICENSE AND COMMERCIALIZATION 
 2.1 License Grant.
In consideration of the payment of Royalties as specified in Section 2.2, BioHelix hereby grants to Great Basin, and Great Basin accepts from BioHelix, in the Field and in the Territory, an irrevocable, non-exclusive license under BioHelix
Intellectual Property Rights to practice the Method and to develop, make, have made, use, offer for sale, sell, have sold, export and import the Product as part of Assay Products, during the Term of this Agreement. 

2.1b Option Grant. ****** 
 2.2 Royalties. In consideration of
the rights granted herein, Great Basin shall pay BioHelix certain royalties as set forth below (the “Royalties”). 

*    *    *    *    *    * 

2.3 Royalty Reports. Payment of the Running Royalties shall be made within forty-five (45) days after the end of each Quarter, and shall be accompanied
by a written report stating the total Net Sales generated in the prior Quarter, and the total Royalties due. All payments hereunder shall be made in U.S. Dollars in the United States by: (i) direct bank transfer to an account designated in
BioHelix’s invoice, (ii) check, or (iii) other form of payment acceptable to and approved in advance by BioHelix. In the event that Great Basin is unable to make such payments in the United States, due solely to its inability to
export funds from a country of the Territory, Great Basin shall notify BioHelix immediately, and if so instructed by BioHelix, deposit all monies due BioHelix in an account of BioHelix in a local bank of BioHelix’s choice within the Territory.

  
 “[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT]” 

  
 3 

 2.4 Intellectual Property Maintenance. During the term of this Agreement, BioHelix hereby agrees to maintain the
BioHelix Intellectual Property Rights in those countries listed in Exhibit B at BioHelix’s expense. 
 ARTICLE 3 

SUPPLY 
 3.1 Supply of Products. Subject to the
terms and conditions of this Agreement, and to the extent that BioHelix is not otherwise in default or breach of the Agreement, Great Basin agrees to purchase from BioHelix, and BioHelix agrees to use reasonable, diligent efforts to supply to Great
Basin, Great Basin’s requirements of Product. 
 3.2 Orders. Great Basin’s orders for Products shall be made pursuant to firm, written purchase
orders. ANY ADDITIONAL OR INCONSISTENT TERMS OR CONDITIONS OF ANY PURCHASE ORDER, ACKNOWLEDGMENT, INVOICE, PACKING SLIP OR SIMILAR STANDARDIZED FORM GIVEN OR RECEIVED PURSUANT TO THIS AGREEMENT SHALL HAVE NO EFFECT AND SUCH TERMS AND CONDITIONS ARE
HEREBY EXCLUDED. FOR THE AVOIDANCE OF DOUBT, SUCH TERMS SHALL BE EXCLUDED NOTWITHSTANDING THE FACT THAT ANY SUCH PURCHASE ORDER, ACKNOWLEDGEMENT, INVOICE, PACKING SLIP OR SIMILAR STANDARDIZED FORM MAY (1) HAVE COME INTO EXISTENCE AFTER THE
EFFECTIVE DATE OF THIS AGREEMENT, OR (2) CONTAIN AN “INTEGRATION CLAUSE” OR SIMILAR LANGUAGE INDICATING THAT SUCH DOCUMENT SUPERCEDES AND/OR AMENDS ALL PRIOR DOCUMENTS AND AGREEMENTS. 

3.3 Specifications. BioHelix will provide Great Basin with written Product Specifications for the Product or Products to be supplied. The parties may from
time to time amend the Product Specifications by mutual written agreement without the necessity of amending this Agreement. Such amended Specifications shall then be deemed the Specifications applicable under this Agreement. 

3.4 Delivery. With respect to exact shipping dates, BioHelix shall use its reasonable efforts to ship to Great Basin quantities of the Product in accordance
with purchase orders submitted in accordance with Section 3.2 above and subject to Section 3.10 below. All Products supplied pursuant to the terms of this Agreement shall be suitably packed for shipment by BioHelix and marked for shipment
to the facility indicated in the Great Basin purchase order (“Delivery Location”). All shipments of Products will be shipped F.O.B. BioHelix, using the carrier selected by Great Basin. All freight costs shall be paid by Great Basin, and
Great Basin shall notify BioHelix whether Great Basin wishes to be billed directly by the carrier or whether BioHelix should prepay the freight cost and add it to Great Basin’s invoice for Products. 

3.5 Acceptance. All shipments and all shipping and other charges shall be deemed correct and accepted unless BioHelix receives from Great Basin, no later than
thirty (30) days after Great Basin’s receipt of a given shipment, a written notice specifying the shipment, the purchase order number, and the nature of the discrepancy between the order and the shipment or the nature of the discrepancy in
the shipping or other charges, as applicable. BioHelix agrees to promptly replace, at no additional expense to Great Basin, any Product that fails to conform in any material respect to the Product Specifications. At BioHelix’s request and
expense, Great Basin shall return to BioHelix all Products that do not conform to the Product Specifications. 
  

“[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 4 

 3.6 Product Pricing. 

(a) Great Basin shall pay BioHelix for Products at the prices set forth in Exhibit A (the “Product Prices”) in effect as of the date of the order.
BioHelix shall charge Great Basin the price applicable to Great Basin’s most recent forecasted volumes for the date on which the order was made. 
 (b)
BioHelix may increase the prices no more than once every 12 months and by no more than the rate of inflation for the previous 12 month period as published in the CPI by the U.S. Department of Labor, provided that any annual price increase may not
exceed three (3) percent of the prices in the previous 12 month period. BioHelix shall provide to Great Basin three months advance notice of a pending price increase, including the amount of the price increase. 

3.8 Invoice. BioHelix shall submit an invoice to Great Basin upon shipment of Product ordered by Great Basin hereunder. All invoices shall include the
relevant Great Basin purchase order number, all Product part numbers, lot numbers of the Products shipped, and the total price of Products purchased. Invoices shall be sent to Great Basin at the following address: Attn: Accounts Payable, 405 S. Main
Street, Ste. 810 Salt Lake City, UT 84111 or such other address as specified in the purchase order therefore. Invoices shall be due and payable within thirty (30) days of Great Basin’s receipt of them. 

3.7 Taxes. 
 (a) Any and all amounts payable hereunder do not
include any government taxes (including without limitation sales, use, excise, and value added taxes) or duties imposed by any governmental agency that are applicable to the export, import, or purchase of the Product (other than taxes on the net
income of BioHelix), and Great Basin shall bear all such taxes and duties. Unless BioHelix is otherwise required to remit by law, Great Basin shall be responsible for remittance of all taxes and duties owed to applicable authorities. When BioHelix
has the legal obligation to collect and/or pay such taxes, the appropriate amount shall be added to, and separately stated on, Great Basin’s invoice and paid by Great Basin, unless Great Basin provides BioHelix with a valid tax exemption
certificate authorized by the appropriate taxing authority. 
 (b) All payments by Great Basin specified hereunder are expressed as net amounts and shall be
made free and clear of, and without reduction for, any withholding taxes. Any such taxes, which are otherwise imposed on payments to BioHelix shall be the sole responsibility of Great Basin. Great Basin shall provide BioHelix with official receipts
issued by the appropriate taxing authority or such other evidence as is reasonably requested by BioHelix to establish that such taxes have been paid. If BioHelix uses a foreign tax credit received by BioHelix as a result of the payment of
withholding taxes by Great Basin and thereby reduces the amount of U.S. income tax that BioHelix otherwise would have paid, BioHelix shall refund to Great Basin the amount of such reduction with respect to such foreign tax credit. 

3.8 Currency Conversion. Conversion of foreign currency to US Dollars shall be calculated in accordance with United States generally accepted accounting
principles and the conversion of 
  
 “[MATERIAL FROM THIS EXHIBIT HAS BEEN
REDACTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 5 

 
foreign currency to US Dollars shall be made at the conversion rate existing in the United States (as reported in the New York Times or the Wall Street Journal) on the last working day of each
royalty period. 
 3.9 Records; Inspection. Great Basin shall keep complete, true and accurate books of accounts and records for the purpose of determining
the amounts payable under this Article 3 for at least three (3) years following the end of the Quarter to which they pertain. Such books and records will be open for inspection during such three (3)-year period by an independent auditor, chosen
by BioHelix and reasonably acceptable to Great Basin, at Great Basin’s site for the purpose of verifying the Running Royalties payable by Great Basin. Such on-site inspections may be made no more than once each Calendar Year, at reasonable
times and on at least thirty (30) days prior written notice, except that in the event of a noncompliance, additional quarterly inspections may be made until the noncompliance has been fully remediated. Inspections conducted under this
Section 3.9 shall be at the expense of BioHelix, unless a variation or error producing an underpayment in amounts payable exceeding 10 percent (10%) of the amount paid for the period covered by the inspection is established in the course
of any such inspection, whereupon all reasonable fees and costs relating to the inspection for such period and any unpaid amounts that are discovered shall be paid by Great Basin. The parties will endeavor to minimize disruption of Great
Basin’s normal business activities to the extent reasonably practicable. 
 3.10 Forecasts. 

Approximately six (6) months prior to the anticipated first commercial sale of an Assay Product, Great Basin shall provide in writing to BioHelix a
rolling forecast by Quarter of quantities, if any, of Great Basin’s anticipated requirements of Product for each Quarter during the twelve (12) month period commencing on the date of such forecast. Such forecast shall not create a binding
obligation on the part of either BioHelix or Great Basin, but shall be used for planning purposes only. Such Quarterly rolling forecasts shall be updated by Great Basin at least thirty (30) days prior to the end of each Quarter, and shall
provide Great Basin’s forecasted orders for the subsequent four Quarters. 
 3.11 Failure to Supply. 

In the event BioHelix is unable to supply Great Basin with a Product: (i) in accordance with Great Basin’s firm orders issued in accordance with
Article 3; (ii) as a result of an uncured material breach by BioHelix of any covenant, representation or warranty contained in this Agreement; (iii) as a result of the bankruptcy or insolvency of BioHelix; or (iv) as a result of an
event of force majeure, BioHelix shall notify Great Basin in writing within thirty (30) days of BioHelix’s knowledge of such inability. BioHelix shall have the opportunity to cure such failure to supply within a one (1) month period
(the “Cure Period”), whether by improving its manufacturing capabilities, having the Product manufactured on BioHelix’s behalf by another party (which meets with all manufacturing and quality requirements specified in this Agreement),
or otherwise. If BioHelix’s failure to supply has not been resolved within the Cure Period, then Great Basin shall have the option to (1) terminate this Agreement immediately on written notice to BioHelix or (2) manufacture, or have
manufactured, the Product, immediately on written notice to BioHelix. 
  

“[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 6 

 3.12 Maintenance and Support. Upon request from Great Basin, BioHelix will provide reasonable technical support
to Great Basin in the development, manufacture and use of Products. 
 3.13 Subdistributors. Subject to all the terms and conditions herein, Great Basin may
appoint third parties within Great Basin’s normal chain of distribution to sell Assay Products (“Subdistributors”), provided that Great Basin shall take such action as shall be reasonably necessary to solicit such
Subdistributor’s cooperation with Great Basin’s confidentiality and intellectual property obligations under this Agreement. 

ARTICLE 4 
 REPRESENTATIONS AND
WARRANTIES 
 4.1 Limited Product Warranty. BioHelix warrants to Great Basin that until the earlier of (a) one (1) year from delivery to an End
User, or (b) fifteen (15) months from delivery to Great Basin each unit of Products (each, a “Product Unit”) will conform to the Specifications therefore, except for any claimed nonconformities that were actually caused by
misuse, neglect, alteration, improper installation, unauthorized repair or improper testing. At Great Basin’s option and BioHelix’s expense, BioHelix shall promptly replace the Product Unit or provide a full refund. 

4.2 Product Return Policies. In the event that a Product Unit fails to conform to the warranty set forth in Section 4.1, during the warranty period
(i) Great Basin shall notify BioHelix in a timely manner in writing that such Product Unit failed to conform and shall furnish a detailed explanation of any alleged nonconformity; and (ii) at BioHelix’s option and election, Great
Basin shall return such nonconforming Product Unit to BioHelix’s manufacturing facility, at BioHelix’s expense. 
 4.3 Intellectual Property.
BioHelix, to the best of its knowledge after conducting a commercially reasonable intellectual property due diligence, represents and warrants that the development, manufacture, sale, distribution and use of the Product, and the practice of the
Method, does not infringe any Intellectual Property rights (including without limitation patent, trademark, copyright, trade secrets and know-how) of a third party. BioHelix represents and warrants that the BioHelix Intellectual Property in the
Product and the Method is valid and enforceable and that BioHelix has all rights and authority to grant the license in Section 2.1 to Great Basin. 

ARTICLE 5 
 TERM AND TERMINATION

 5.1 Term. The term of this Agreement shall commence on the Effective Date and continue in full force until the expiration or invalidation, on a
jurisdiction by jurisdiction basis, of all patents covering Great Basin Assay Products and licensed under this Agreement, unless earlier terminated in accordance with this Article 5 (the “Term”). BioHelix shall provide Great Basin with at
least ninety (90) days advance written notice of the expiration of the last of the Licensed Patents. Upon expiration of the last Licensed Patent, Great Basin’s obligation to pay Running Royalties to BioHelix shall cease, and BioHelix shall
continue to supply Products to Great Basin, at Great Basin’s option, at prices to be determined by the parties. 
  

“[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 7 

 5.2 Termination for Breach. This Agreement may be terminated by either party by written notice of termination
effective immediately: (i) if the other party breaches any material term or condition of this Agreement and fails to remedy the breach within sixty (60) days after being given written notice thereof stating the non-breaching party’s
intent to terminate; or (ii) if the other party ceases business activities or becomes bankrupt or insolvent; provided, however, that termination under this Section 6.2 shall not relieve Great Basin of any payment obligations incurred under
this Agreement prior to the termination. 
 5.3 Termination by Great Basin. Great Basin may terminate this Agreement for any reason on thirty (30) days
written notice to BioHelix, with no further liability or financial obligation to BioHelix, other than the royalty obligations for product sold as set forth in 2.2(e) incurred up to the date on which termination is effective. 

5.4 Wind-down. Upon expiration or termination of this Agreement for any reason, Great Basin shall have the option to issue a final order of Products to
BioHelix, not to exceed Great Basin’s most recent 12-month forecast, and BioHelix shall manufacture and supply such Products to Great Basin according to the terms and conditions of this Agreement. 

5.5 Survival. It is understood that termination of this Agreement shall not relieve a party from any liability, which, at the time of such termination, has
already accrued to the other party. In addition, the following provisions shall survive any expiration or termination of this Agreement: Sections 3.09, 3.10, 3.11, 3.13, 4.1, 4.2, 4.3, 5.1, 6.1, 7.1, 7.2, 8.1, 8.5 and 8.6, as well as Exhibit D.
Except as otherwise expressly provided in this Section 5, all other rights and obligations of the parties shall terminate upon termination of this Agreement. 

ARTICLE 6 
 CONFIDENTIALITY AND
PUBLICITY 
 6.1 Confidentiality. The parties agree that they shall continue to be bound by the terms of the Mutual Non-Disclosure Agreement executed
between them, dated January 31, 2007, throughout the Term of this Agreement. The terms of the Mutual Non-Disclosure Agreement, as incorporated herein by reference, shall survive the expiration or termination of this Agreement. 

6.2 Publicity. Neither party shall disclose the existence of this Agreement to the public or any third parties without the prior written consent of the other
party, provided that the parties shall have the right to disclose information, including, if applicable, the Agreement, as necessary to meet its obligations under the U.S. federal and state securities laws. The parties agree to permit the other
party to make a press release announcing this relationship upon execution of this Agreement, subject to prior approval by each of the parties. Once a party has obtained the other party’s consent to issue any press release or other public
disclosure, the party may subsequently release or issue such approved information without the need to obtain additional approval from the other party for each such subsequent use. 

ARTICLE 7 
 INDEMNIFICATION 

7.1 BioHelix Indemnity. BioHelix shall defend, indemnify and hold, its officers, directors, employees and agents (“Great Basin Indemnities”)
harmless from and against any claim, 
  
 “[MATERIAL FROM THIS EXHIBIT HAS BEEN
REDACTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 8 

 
complaint, suit, proceeding or cause of action (collectively and individually referred to as a “Claim”) brought against Great Basin Indemnities by a third party resulting from a defect
in the Product’s design or manufacture by BioHelix (and not resulting from any alteration of the Product by Great Basin), and BioHelix shall pay resulting damages or settlement amounts finally awarded against Great Basin Indemnities (including
reasonable attorneys’ fees, legal expenses and court costs) to the extent attributable to such Claim but no more in total than the maximum limit of liability insurance that BioHelix possesses for product liability at that time. Great Basin
shall (i) promptly notify BioHelix of each Claim, (ii) provide BioHelix with sole control over the defense and/or settlement thereof, and (iii) at BioHelix’s request and expense, provide full information and reasonable assistance
to BioHelix with respect to such Claims. 
 7.2 Great Basin Indemnity. Except for warranty claims for which BioHelix is liable under this Article 7, Great
Basin agrees to indemnify and hold BioHelix, its officers, directors, employees and agents (“BioHelix Indemnities”) harmless from and against any cost, loss, damages, liability or expenses (including attorneys’ fees) arising out of
third party claims brought against BioHelix Indemnities arising out of or relating to Great Basin’s manufacture, development, design, use, handling, storage, importation, sale, distribution or other disposition of Assay Products, unless such
claims are attributable to the negligence of BioHelix or a malfunction or defect in the Products supplied by BioHelix hereunder. 
 ARTICLE 8

 MISCELLANEOUS 
 8.1 Governing Law. THIS
AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE UNITED STATES AND THE STATE OF MASSACHUSETTS WITHOUT REFERENCE TO CONFLICT OF LAWS PRINCIPLES AND EXCLUDING THE 1980 U.N. CONVENTION ON CONTRACTS FOR
THE INTERNATIONAL SALE OF GOODS. 
 8.2 Dispute Resolution. In the event of any dispute arising out of or related to this Agreement, the parties hereto
shall refer such dispute to the CEO of Great Basin and the CEO of BioHelix for attempted resolution by good faith executive negotiations within thirty (30) days after such referral is made. In the event such officers are unable to resolve such
dispute within such thirty (30) day period, either party hereto may assert its rights in a manner of its choosing. 
 8.3 Force Majeure. Except with
respect to payment obligations, nonperformance of any party shall be excused to the extent that performance is rendered impossible by strike, fire, earthquake, flood, governmental acts or orders or restrictions, failure or delay of suppliers, or any
other reason where failure to perform is beyond the reasonable control of the nonperforming party. The party affected by force majeure shall promptly and timely notify the other party of the existence thereof, the expected delays, and the estimated
effect upon its performance hereunder. The party affected by force majeure shall use its reasonable efforts to limit the resulting delay in its performance and shall resume its performance as soon as reasonably possible. 

8.4 Assignment. Great Basin may assign its rights and obligations under this Agreement in the event of a change of control or the sale of substantially all of
its assets, in which case the Agreement shall be binding upon and inure to the benefit of such successor entity. In the event 
  

“[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 9 

 
that BioHelix enters into discussions with any party regarding a change of control (i.e, merger, acquisition, or sale of substantially all of the assets relating to the Product), BioHelix shall
provide Great Basin with written notification within 30 days of the initiation of such discussions and the successor of BioHelix shall assume all of BioHelix’s rights, duties, covenants and obligations of this Agreement. 

8.5 Notices. Any notice or report required or permitted to be given or made under this Agreement by either party shall be in writing and delivered by courier,
certified mail or by confirmed facsimile to the other party at its address indicated below (or to such other address as a party may specify by notice hereunder). 

If to BioHelix: 
 BioHelix Corporation 

32 Tozer Road 
 Beverly, Massachusetts 01915 

Attention: Huimin Kong, CEO 
 Fax: (978)-927-3382 

If to Great Basin: 
 Great Basin Scientific Inc. 

405 South Main Street 
 Suite 810 

Salt Lake City, UT 84111 
 Attn: Jeffrey Selander 

FAX: 801 596-2746 
 8.6 Limitation of Liability. 

(a) General. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST OR
ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), ARISING FROM OR RELATING TO THIS AGREEMENT OR THE SUBJECT MATTER HEREOF, WHETHER BASED IN CONTRACT, TORT (INCLUDING NEGLIGENCE OR STRICT LIABILITY) OR OTHERWISE, AND EVEN IF SUCH PARTY IS
ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. THE LIMITATIONS IN THIS SECTION 10.6 SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN. 

(b) Upon Termination. In the event of termination of this Agreement by either party in accordance with any of the provisions hereof, neither party shall be
liable to the other, because of such termination, for compensation, reimbursement or damages on account of the loss of prospective profits or anticipated sales or on account of expenditures, inventory, investments, leases or commitments in
connection with the business or goodwill of BioHelix or Great Basin. Termination shall not, however, relieve either party of obligations incurred prior to the termination. 
  

“[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 10 

 8.7 Headings. Headings included herein are for convenience only, do not form a part of this Agreement and shall
not be used in any way to construe or interpret this Agreement. 
 8.8 Non-Waiver. Any waiver of the terms and conditions hereof must be explicitly in
writing. The waiver by either of the parties of any breach of any provision hereof by the other shall not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself. 

8.9 Severability. Should any section, or portion thereof, of this Agreement be held invalid by reason of any law, statute or regulation existing now or in the
future in any jurisdiction by any court of competent authority or by a legally enforceable directive of any governmental body, such section or portion thereof shall be validly reformed so as to reflect the intent of the parties as nearly as possible
and, if not capable of reform, shall be deemed divisible and deleted with respect to such jurisdiction, but the Agreement shall not otherwise be affected. 

8.10 Further Assurances. Each party hereto agrees to do and perform all such further acts and things and shall execute and deliver such other agreements,
certificates, instruments and documents necessary or that the other party may deem advisable in order to carry out the intent and accomplish the purposes of this Agreement and to evidence, perfect or otherwise confirm its rights hereunder. 

8.11 Independent Contractors. The relationship of Great Basin and BioHelix established by this Agreement is that of independent contractors. Nothing in this
Agreement shall be construed to create any joint venture, partnership, agent/principal or employee/employer relationship, or any other relationship between Great Basin and BioHelix. Neither party shall have any right, power or authority to assume,
create or incur any expense, liability or obligation, express or implied, on behalf of the other. 
 8.12 Insurance. During the term of this Agreement, each
party shall, at its sole cost and expense, obtain and keep in force a policy of commercial general liability insurance with bodily injury, death and property damage limits of not less than $1,000,000 per occurrence and $3,000,000 in the aggregate,
plus an umbrella policy of at least $5,000,000. Each party shall also maintain product liability insurance with limits of not less than 5,000,000 (including umbrella policy). Each party shall cause the other to be named as an additional insured on
all of its above policies. Within ninety (90) days following the Effective Date, each party shall furnish the other party with a certificate of insurance evidencing the insurance required hereunder. Each party will use reasonable efforts to
provide to the other party (i) at least thirty (30) days prior written notice of any cancellation, termination or material change of such insurance coverage and (ii) prompt written notice of the occurrence of any event that is
reasonably likely to result in a claim being made under such insurance policy. 
 8.13 Entire Agreement. The terms and provisions contained in the
Agreement, including the Exhibits hereto, constitute the entire agreement between the parties regarding the subject matter hereof and shall supersede all previous communications, representations, agreements or understandings, either oral or written,
between the parties concerning such subject matter. The parties agree that the terms and conditions of this Agreement shall prevail, notwithstanding contrary or additional terms, in any purchase order, sales acknowledgment, invoice, packing slip,

  
 “[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT]” 

  
 11 

 
confirmation or any other document issued by either party affecting the sale of Product. No agreement or understanding varying or extending this Agreement shall be binding upon either party
hereto, unless set forth in a writing which specifically refers to the Agreement signed by duly authorized officers or representatives of the respective parties, and the provisions hereof not specifically amended thereby shall remain in full force
and effect. 
 8.14 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but which together shall
constitute one and the same instrument. 
 IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to execute this
Agreement. 
  

									
	GREAT BASIN CORPORATION	 		 	BIOHELIX CORPORATION
					
	By:	 	 /s/ Ryan Ashton
	 		 	By:	 	 /s/ Huimin Kong

	Name:	 	Ryan Ashton	 		 	Name:	 	Huimin Kong
	Title:	 	President and CEO	 		 	Title:	 	CEO and President

  
 “[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 12 

 EXHIBIT A 

[Redacted] 
  

“[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 13 

 EXHIBIT B 

[Redacted] 
  

“[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 14 

 EXHIBIT C 

[Redacted] 
  

“[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 15 

 EXHIBIT D 

TERMS AND CONDITIONS OF LICENSE 
  

	1.	Definitions 

 Capitalized terms in these Terms and Conditions of License (herein called “License”) not
defined herein shall have the meaning ascribed to them in the License and Supply Agreement (herein called “Agreement”), which definitions shall be incorporated herein by reference. In addition, the following additional capitalized terms
used in this License shall have the following meanings. 
 “Know-how” means confidential and/or proprietary technical information,
techniques, processes, methods, data, assays, substances and materials, and other information in a person’s or entity’s possession that is not generally available to the public. 

“Licensee” means Great Basin. 

“Licensor” means BioHelix. 
  

	2.	Grant 

 Effective on the Date of Grant, Licensor hereby grants, subject to the terms and conditions set forth in
this License, to Licensee, and Licensee hereby accepts, a perpetual (except as set forth below in this License), non-exclusive, non-transferable (except as set forth below in this License), license under BioHelix Intellectual Property Rights to
manufacture, have manufactured, use, import, offer to sell, and sell Products in the specified Field. No right to sublicense pursuant to this License is granted. 
  

	3.	Royalties and Payments 

 3.1 ****** 

3.2 ****** 
 3.3 All payments set forth hereunder shall be made
by Licensee in US dollars. 
  

	4.	Intellectual Property Rights and Obligations 

 4.1 Licensor at its sole discretion shall have the right to
abandon or cease to prosecute or maintain any issued patent or patent application constituting BioHelix Intellectual Property Rights; provided, however, that Licensor shall give Licensee written notice of such decision and Licensee shall have the
right, exercisable within sixty (60) days after receipt of such written notice from Licensor, and exercised by providing written notice to Licensor, to take over the rights to prosecute and maintain any issued patent or patent application
constituting BioHelix Intellectual Property Rights, and to assume responsibility for payment of all costs, fees and expenses related thereto. 
  

“[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 16 

 4.2 Except as set forth in Section 4.1 of this License, Licensee shall have no responsibility or obligation
for any costs, fees and expenses incurred in connection with the prosecution and maintenance of any patents and patent applications under BioHelix Intellectual Property Rights. 

 

	5.	Confidentiality 

 5.1 The parties shall abide by the Confidentiality provision (Section 6.1) of the Agreement,
which shall be incorporated herein by reference. 
  

	6.	Assignment 

 The rights and obligations of a party under this License with respect to assignments shall be
governed by Section 8.4 of the Agreement, which shall be incorporated herein by reference. 
  

	7.	Term and Termination 

 The term of this License shall commence on the Date of Grant and expire upon the
expiration of the last to expire of the Licensed Patents. Licensor may terminate the licenses and rights granted hereunder in the event Licensee at any time fails to pay royalties when due and payable hereunder; provided Licensor has first given
Licensee written notice of such failure and a period of at least thirty (30) days thereafter to make such payment and Licensee has not made such payment within said thirty (30) day period. Licensee may terminate this License on sixty
(60) days prior written notice to Licensor. In the event of any such termination, all obligations of the parties arising on or before the date of termination shall remain in effect including without limitation any obligations to pay royalties.

  
 “[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT]” 

  
 17 

 First Amendment to the License and Supply Agreement 

This First Amendment to the License and Supply Agreement (this “Amendment”) is entered into on this 25th day of June, 2010, by and between Great
Basin Scientific Corporation, a Nevada corporation (“Great Basin”), and BioHelix Corporation, a Massachusetts corporation (“BioHelix”). This Amendment amends that certain License and Supply Agreement dated January 9, 2009,
by and between Great Basin and BioHelix (the “Original Agreement”) and shall become effective upon satisfaction of the condition provided in Section 4 below. 

1. Section 1.6 (Field(s)) of the Original Agreement is hereby amended by deleting it entirely and replacing it with the following: 

1.6 “Field(s)” means human diagnostic testing using the amplification method disclosed and defined in the BioHelix Intellectual
Property Rights in combination with Great Basin’s solid surface chip based detection methods for the detection of any pathogen identified in writing by Great Basin and delivered to BioHelix during the term of this Agreement (each a “Target
Pathogen”). By way of example, the Field may include screening for the presence, identity, subtype and antibiotic resistance profile of any Target Pathogen identified by Great Basin. The number of Target Pathogen that may be selected by Great
Basin during the term of this Agreement shall be subject to the terms and conditions set forth in Sections 2.1 and 2.1b. 
 2. Section 2.1 (License
Grant) of the Original Agreement is hereby amended by deleting it entirely and replacing it with the following: 
 2.1 License Grant. In
consideration of the payment of Royalties as specified in Section 2.2, BioHelix hereby grants to Great Basin, and Great Basin accepts from BioHelix an irrevocable, non-exclusive license under BioHelix Intellectual Property Rights in the Field
and in the Territory to practice the Method and to develop, make, have made, use, offer for sale, sell, have sold, export and import the Product as part of Assay Products, during the Term of this Agreement. Unless the Option (as defined in
Section 2.1b below) is timely exercised, the number of Target Pathogens subject to this Agreement shall be limited to three (3) Target Pathogens, one of which shall be Staphylococcal species identification and associated drug resistance
markers, including the mecA gene. 
 3. Section 2.1b (Option Grant) of the Original Agreement is hereby amended by deleting it entirely and replacing
it with the following: 
 2.1b Option Grant. ****** 

4. In consideration of the amendment and extension of the Option provided herein, a non-refundable Option Extension Fee of ****** is due by July 9, 2010
from Great Basin to BioHelix. This Amendment will become effective upon receiving the ****** Option Extension Fee from Great Basin. The ****** Option Extension Fee is creditable to the licensing fee and/or Royalties. 

IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to execute this First Amendment to the License and
Supply Agreement. 
  

									
	GREAT BASIN CORPORATION	 		 	BIOHELIX CORPORATION
					
	By:	 	/s/ Robert Jenison	 		 	By:	 	/s/ Huimin Kong
	Name:	 	Robert Jenison	 		 	Name:	 	Huimin Kong
	Title:	 	Chief Technology Officer	 		 	Title:	 	CEO and President

  
 “[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 18 

 Second Amendment to the License and Supply Agreement 

This Second Amendment to the License and Supply Agreement (this “Second Amendment”) is entered into on this 18th day of January, 2011, by and
between Great Basin Scientific Corporation, a Nevada corporation (“Great Basin”), and BioHelix Corporation, a Massachusetts corporation (“BioHelix”). This Second Amendment amends that certain License and Supply Agreement dated
January 9, 2009, as amended by the First Amendment to the License and Supply Agreement dated June 25, 2010, by and between Great Basin and BioHelix (as amended, the “Agreement”) and shall become effective upon satisfaction of the
condition provided in Section 2 below. 
 1. Section 2.1b (Option Grant) of the Original Agreement is hereby amended by deleting it entirely and
replacing it with the following: 
 2.1b Option Grant. ****** 

2. ****** 
 IN WITNESS WHEREOF, the parties hereto have caused
their duly authorized representatives to execute this Second Amendment to the License and Supply Agreement. 
  

									
	GREAT BASIN CORPORATION	 		 	BIOHELIX CORPORATION
					
	By:	 	/s/ Robert Jenison	 		 	By:	 	/s/ Huimin Kong
					
	Name:	 	Robert Jenison	 		 	Name:	 	Huimin Kong
					
	Title:	 	Chief Technology Officer	 		 	Title:	 	President and CEO

  
 “[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]” 

  
 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]